Equities research analysts predict that Medpace Holdings Inc (NASDAQ:MEDP) will post earnings of $0.67 per share for the current quarter, Zacks reports. Five analysts have issued estimates for Medpace’s earnings. The lowest EPS estimate is $0.64 and the highest is $0.68. Medpace reported earnings of $0.39 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 71.8%. The business is scheduled to issue its next earnings report on Monday, February 25th.
According to Zacks, analysts expect that Medpace will report full-year earnings of $2.50 per share for the current financial year, with EPS estimates ranging from $2.47 to $2.52. For the next year, analysts forecast that the firm will post earnings of $2.89 per share, with EPS estimates ranging from $2.84 to $2.96. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Medpace.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. Medpace had a return on equity of 15.86% and a net margin of 10.84%. The company had revenue of $179.00 million for the quarter, compared to the consensus estimate of $175.07 million. During the same quarter in the previous year, the business earned $0.40 EPS. Medpace’s revenue was up 44.4% compared to the same quarter last year.
Shares of NASDAQ:MEDP opened at $58.74 on Wednesday. Medpace has a 1 year low of $31.70 and a 1 year high of $65.09. The stock has a market cap of $2.07 billion, a P/E ratio of 38.64, a price-to-earnings-growth ratio of 1.46 and a beta of 1.41. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.25.
In other Medpace news, major shareholder Medpace Limited Partnership sold 5,224,997 shares of Medpace stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $54.75, for a total transaction of $286,068,585.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 114,983 shares of Medpace stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $59.31, for a total value of $6,819,641.73. Following the sale, the chief executive officer now directly owns 351,851 shares in the company, valued at $20,868,282.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,621,556 shares of company stock worth $309,490,974. Insiders own 29.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Granite Investment Partners LLC boosted its position in Medpace by 0.3% during the 2nd quarter. Granite Investment Partners LLC now owns 260,447 shares of the company’s stock valued at $11,199,000 after acquiring an additional 864 shares in the last quarter. Victory Capital Management Inc. boosted its position in Medpace by 15.9% during the 2nd quarter. Victory Capital Management Inc. now owns 7,091 shares of the company’s stock valued at $305,000 after acquiring an additional 974 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Medpace by 57.1% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock valued at $178,000 after acquiring an additional 1,507 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Medpace by 26.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 7,983 shares of the company’s stock valued at $278,000 after acquiring an additional 1,673 shares in the last quarter. Finally, BlueMountain Capital Management LLC boosted its position in Medpace by 9.3% during the 2nd quarter. BlueMountain Capital Management LLC now owns 21,710 shares of the company’s stock valued at $934,000 after acquiring an additional 1,848 shares in the last quarter. 40.22% of the stock is currently owned by institutional investors and hedge funds.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.